{"queries":{"request":[{"totalResults":"111","searchTerms":"Natrecor"}],"nextPage":[{"startIndex":11}]},"searchInformation":{"totalResults":"111"},"items":[{"title":"Scios Inc. Announces Agreement with Department of Justice ...","link":"https://www.jnj.com/media-center/press-releases/scios-inc-announces-agreement-with-department-of-justice-regarding-natrecor","snippet":"Scios Inc. Announces Agreement with Department of Justice Regarding \nNATRECOR®. Raritan, NJ (October 5, 2011) – Today Scios Inc. announced an ...","pagemap":{}},{"title":"Scios Submits Interim Report to FDA on NATRECOR®(nesiritide ...","link":"http://www.investor.jnj.com/releasedetail.cfm?releaseid=182976","snippet":"Jan 3, 2006 ... The interim report contains two additional deaths that had occurred within 30 \ndays after treatment with NATRECOR® but had not been initially ...","pagemap":{}},{"title":"Scios Inc. Receives Subpoena on NATRECOR(R) (Nesiritide ...","link":"http://www.investor.jnj.com/releasedetail.cfm?releaseid=169260","snippet":"Jul 20, 2005 ... FREMONT, Calif., July 20, 2005 /PRNewswire-FirstCall via COMTEX/ -- Scios Inc.\n, a Johnson & Johnson company, has received a subpoena ...","pagemap":{}},{"title":"Johnson & Johnson to Acquire Scios Inc.; Cash for Stock ...","link":"http://www.investor.jnj.com/releasedetail.cfm?releaseid=101418","snippet":"Feb 10, 2003 ... Scios' product NATRECOR(R)is the first novel agent approved for congestive \nheart failure (CHF) in more than a decade. NATRECOR(R) is a ...","pagemap":{}},{"title":"Johnson & Johnson and Scios Inc. Announce Early Termination Of ...","link":"http://www.investor.jnj.com/releasedetail.cfm?releaseid=105629","snippet":"Scios' product NATRECOR(R)is the first novel agent approved for congestive \nheart failure (CHF) in more than a decade. NATRECOR(R) is a recombinant form\n ...","pagemap":{}},{"title":"Scios Announces Results of ASCEND Heart Failure Study at the ...","link":"http://www.investor.jnj.com/releasedetail.cfm?releaseid=530325","snippet":"Nov 14, 2010 ... CHICAGO, November 14, 2010 -- Scios Inc. announced today that the landmark \ninvestigational study of NATRECOR® (nesiritide) for the ...","pagemap":{}},{"title":"Johnson & Johnson and its Subsidiaries, Janssen Pharmaceuticals ...","link":"http://www.investor.jnj.com/releasedetail.cfm?releaseid=804083","snippet":"Nov 4, 2013 ... The agreement also resolves allegations related to the sales and marketing of \nINVEGA®, NATRECOR® by Scios Inc. , and allegations related ...","pagemap":{}},{"title":"Johnson & Johnson Reports Fourth-Quarter and Full-Year 2007 ...","link":"http://www.investor.jnj.com/releasedetail.cfm?releaseid=288862","snippet":"Jan 22, 2008 ... ... related to NATRECOR (nesiritide); and a gain of $267 million for international \ntax restructuring. Full-year 2006 net earnings included after-tax ...","pagemap":{}},{"title":"Johnson & Johnson - Definitive Proxy Statement","link":"http://www.investor.jnj.com/secfiling.cfm?filingid=950157-03-68&cik=","snippet":"Scios' product NATRECOR(R)is the first novel agent approved for congestive \nheart failure (CHF) in more than a decade. NATRECOR(R) is a recombinant form\n ...","pagemap":{}},{"title":"Johnson & Johnson Expects to Incur Special Charge in Second ...","link":"http://www.investor.jnj.com/releasedetail.cfm?releaseid=681623","snippet":"Jun 8, 2012 ... ... civil litigation matters related to RISPERDAL® (risperidone), INVEGA® (\npaliperidone), NATRECOR® (nesiritide) and Omnicare, Inc.","pagemap":{}}]}